These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21518936)

  • 1. The impact of new cardiovascular device technology on health care costs.
    Groeneveld PW; Polsky D; Yang F; Yang L; Epstein AJ
    Arch Intern Med; 2011 Jul; 171(14):1289-91. PubMed ID: 21518936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular device technology and health care cost.
    Dean LS
    Arch Intern Med; 2011 Oct; 171(18):1689; author's reply 1689. PubMed ID: 21987207
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-eluting stents: more dollars than sense?
    Garg S; Eisenberg MJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1188-9. PubMed ID: 20129544
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Can PCI with drug-eluting stents replace coronary artery bypass surgery? A comparative economic analysis regarding both therapeutic options based on clinical 12-month data reflecting the German social health care insurance system].
    Fricke FU; Silber S
    Herz; 2005 Jun; 30(4):332-8. PubMed ID: 15965811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent.
    Mattke S; Hanson M; Dallmann AC; Bentele M
    Cardiovasc Revasc Med; 2019 Sep; 20(9):752-757. PubMed ID: 30638888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
    Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
    JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs of drug-eluting coronary stents among Medicare beneficiaries.
    Groeneveld PW; Matta MA; Greenhut AP; Yang F
    Am Heart J; 2008 Jun; 155(6):1097-105. PubMed ID: 18513525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-generation drug-eluting stents and the continuous need for rapidly available real-world data.
    Mukherjee D; Moliterno DJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1236-9. PubMed ID: 20129550
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of multiple drug-eluting stent percutaneous coronary intervention and surgical revascularization in patients with multivessel coronary artery disease: one-year clinical results and total treatment costs.
    Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
    J Invasive Cardiol; 2007 Nov; 19(11):469-75. PubMed ID: 17986722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
    Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data.
    Remak E; Manson S; Hutton J; Brasseur P; Olivier E; Gershlick A
    EuroIntervention; 2010 Feb; 5(7):826-32. PubMed ID: 20142198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials.
    Ferko N; Ferrante G; Hasegawa JT; Schikorr T; Soleas IM; Hernandez JB; Sabaté M; Kaiser C; Brugaletta S; de la Torre Hernandez JM; Galatius S; Cequier A; Eberli F; de Belder A; Serruys PW; Valgimigli M
    Catheter Cardiovasc Interv; 2017 May; 89(6):994-1002. PubMed ID: 27527508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
    Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevaliers B; DiMario C; Fajadeto J; Gitt A; Guagliumi G; Hillege HL; James S; Jüni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Berenger M; Boam A; Calle JP; Campo G; Carlier S; de Schepper J; Di Bisceglie G; Dobbels H; Farb A; Ghislain JC; Hellbardt S; ten Hoedt R; Isaia C; de Jong P; Lekehal M; LeNarz L; Mhullain FN; Nagai H; Patteet A; Paunovic D; Potgieter A; Purdy I; Raveau-Landon C; Ternstrom S; Van Wuytswinkel J; Waliszewski M;
    EuroIntervention; 2009 Jan; 4(4):427-36. PubMed ID: 19284063
    [No Abstract]   [Full Text] [Related]  

  • 16. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
    Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-Eluting Stent Use Among Low-Income Patients in Maharashtra After Statewide Price Reductions.
    Duggal B; Gokul B; Duggal M; Saunik S; Singh P; Agrawal A; Singh K; Wadhera P; Anupindi R; Nallamothu BK
    Circ Cardiovasc Interv; 2019 Apr; 12(4):e007757. PubMed ID: 30929509
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).
    Amin AP; Reynolds MR; Lei Y; Magnuson EA; Vilain K; Durtschi AJ; Simonton CA; Stone GW; Cohen DJ
    Am J Cardiol; 2012 Sep; 110(6):765-70. PubMed ID: 22651880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
    Jiang M; You JHS
    Clin Cardiol; 2017 Oct; 40(10):789-796. PubMed ID: 28683175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target lesion revascularization after bare-metal or drug-eluting stents: clinical presentation and outcomes.
    Vidi VD; Arora N
    J Invasive Cardiol; 2010 Jun; 22(6):271-2. PubMed ID: 20516506
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.